Is the price fair?
What CYTK's price assumes
Cytokinetics, Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.08× revenue.
0.08
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 1.19
EV / sales
Details›
- EV / EBIToperating margin −1046%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.19
- Market capitalisation
- $11.0B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.